HHS Public Access

Author manuscript

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2021 November 01.

Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2021 May ; 30(5): 990–999. doi:10.1158/1055-9965.EPI-20-1389.

Differential associations of SLCO transporters with prostate cancer aggressiveness between African Americans and European Americans

Li Tang[1], **Qianqian Zhu**[2], **Zinian Wang**[1], **Clayton M. Shanahan**[1], **Jeannette T. Bensen**[3], **Elizabeth T.H. Fontham**[4], **Gary J. Smith**[5], **Elena A. Pop**[5], **Gissou Azabdaftari**[6], **James L. Mohler**[5], **Yue Wu**[5]

[1]Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY

[2]Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY

[3]Department of Epidemiology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC

[4]School of Public Health, Louisiana State University, Baton Rouge, LA

[5]Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

[6]Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Abstract

Background: Androgen receptor signaling is crucial to prostate cancer aggressiveness. Members of the solute carrier family of the organic anion transporting peptides (SLCOs) are potential regulators of androgen availability in prostate tissue. It remains unknown whether genetic variations in SLCOs contribute to the differences in prostate cancer aggressiveness in African Americans (AAs) and European Americans (EAs).

Methods: Single nucleotide polymorphisms (SNPs) in 11 SLCO members were selected with addition of 139 potentially functional SNPs and 128 ancestry informative markers. A total of 1045 SNPs were genotyped and analyzed in 993 AAs and 1057 EAs from the North Carolina-Louisiana Prostate Cancer Project. Expression and cellular localization of SLCOs were examined using quantitative RT-PCR, immunohistochemistry, and *in situ* RNA hybridization in independent sets of prostate cancer cases.

Results: Significant associations with prostate cancer characteristics were found for SNPs in *SLCO2A1* and *SLCO5A1*. The associations differed by race (P for interaction <0.05). SNPs in *SLCO2A1* were associated with reduced tumor aggressiveness and low Gleason score in AAs; whereas, SNPs in *SLCO5A1* were associated with high clinical stage in EAs. In prostate tissue,

Corresponding author: Li Tang, Department of Cancer Prevention and Control, Basic Science Building 708, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263. Phone: 716-845-8247; Fax: 716-845-4643; li.tang@roswellpark.org.

Conflict of interest: The authors declare no potential conflicts of interest.

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

SLCO2A1 and SLCO5A1 were the most expressed SLCOs at the mRNA level and were expressed predominantly in prostate endothelial and epithelial cells at the protein level, respectively.

Conclusions: SLCO2A1 and SLCO5A1 play important but different roles in prostate cancer aggressiveness in AAs versus EAs.

Impact: The finding calls for consideration of racial differences in biomarker studies of prostate cancer and for investigations on functions of SLCO2A1 and SLCO5A1 in prostate cancer.

Keywords

SLCO transporter; polymorphism; aggressiveness; prostate cancer; North Carolina-Louisiana Prostate Cancer Project (PCaP)

Introduction

Compared to European Americans (EAs), African Americans (AAs) suffer higher incidence of, and greater mortality from, prostate cancer (PCa) (1). The racial difference in PCa survival between AAs and EAs could be reduced by improving access to care (2). However, the evidence for racial difference in the biology of PCa is substantial (3). Androgen-stimulated androgen receptor (AR) signaling is crucial to progression and survival of PCa cells throughout all stages of PCa (4-6). Expressions of a cell proliferation marker Ki-67 and AR were found higher in prostate biopsy specimens from AAs than EAs after controlling age and Gleason score (7). Further, percentage of AR-positive cells and AR expression were higher in benign and malignant prostate tissue from AAs when compared to those from EAs (8). These findings suggest that AR activity, and subsequently, AR-driven cell progression may be up-regulated in PCa in AAs relative to EAs. Although serum androgen concentrations are similar between adult AAs and EAs, tissue androgen concentrations vary among individuals (9). We reported that the ability to accumulate androgens differed among PCa cell lines, and these differences were mediated by a selective, active transport mechanism (10,11).

The solute carrier family of organic anion transporting peptides (SLCO) family is comprised of 11 transmembrane transporters that mediate cellular uptake of a wide range of chemicals that include androgens (12-16). Expression of SLCO transporters was altered in malignant tissues compared to benign tissues (14), and was associated with PCa outcomes (12,13,17). Existing studies that examined genetic variations of SLCO transporter genes in PCa primarily focused on clinical outcomes and included only one or two SLCO family members (12,13,17-20). To our knowledge, there has not been a systematic investigation of genetic variants of SLCO transporters in PCa, nor an investigation of their roles in racial disparity in PCa aggressiveness. Here, we reported a comprehensive examination of single nucleotide polymorphisms (SNPs) of all 11 SLCO transporter genes in relation to PCa characteristics in AA and EA participants in the North Carolina-Louisiana PCa Project (PCaP), a population-based, case-only study of racial/ethnic differences in PCa (21). Expression profiles and cellular localization of SLCO transporters in malignant and benign prostate tissues also were examined in independent sets of PCa cases. We hypothesized that differences in genetic variations or expression of SLCO transporters may regulate the availability of androgens to

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

PCa cells, in that high or more efficient uptake of androgens may lead to development of more aggressive PCa, thus contribute to the differences in PCa aggressiveness between AAs and EAs.

Materials and Methods

Study population of PCaP

The genotyping study utilized data and samples collected from PCaP participants. Eligible participants were residents of the North Carolina (NC) or Louisiana (LA) study areas who had a first diagnosis of histologically confirmed adenocarcinoma of the prostate, were 40-79 years of age at diagnosis, and self-identified as AA/Black or as Caucasian/Caucasian-American (EA)/White (21). PCaP enrolled 2246 men from 2003 to 2009. A subset of participants (N=2115) with germline DNA samples and relevant clinical and epidemiological data were included in the study. Informed written consent was obtained from each participant for the release and use of their medical records and biological samples for research. The research was conducted in accordance with recognized ethical guidelines and was approval by Roswell Pak Comprehensive Cancer Center and other relevant Institutional Review Boards. The genotyping data generated in this study can be accessed upon request to PCaP.

PCaP epidemiologic and clinical data

Epidemiologic data were collected by a series of structured questionnaires administered at time of enrollment by a registered nurse during an in-person interview, which occurred averagely within 3-4 months after PCa diagnosis (21). Epidemiologic information included demographics, race/ethnicity, personal/family history of cancer, and PCa screening history. Since the study focused on racial disparity in PCa aggressiveness, only the data from self-reported race were considered in the analysis along with ancestry data from genotyping.

Clinical data were extracted from medical records and tumor information was derived independently based on a standardized protocol. Clinical data included tumor stage, Gleason grade, history of PCa screening examinations, and laboratory assays at or near diagnosis. Combinations of the Gleason score, clinical stage, and PSA at diagnosis were used to define PCa aggressiveness in 3 categories: highly aggressive (Gleason score 8, or PSA > 20 ng/mL, or Gleason score = 7 and clinical stage T3-T4); non-aggressive (Gleason score < 7 and stage T1-T2 and PSA < 10 ng/mL); and intermediate aggressive (all other cases). The definition was developed by PCaP based on the literature reviews of risk factors and characteristics that are strongly associated with survival and aligned with other risk classification systems (21,22).

SNP selection, genotyping, and quality control

Tag SNPs were selected for all 11 members of the SLCO family based on HapMap genotype and linkage disequilibrium (LD) data from the YRI (Yoruba in Ibadan, Nigeria) and CEU (Utah residents with Northern and Western European ancestry) populations to most closely resemble AA and EA populations respectively, with LD threshold (r^2) 0.8 and minor allele frequency (MAF) 5%. The panel of SNPs included 139 potentially functional SNPs

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

identified using HuGE Literature Finder on significant associations and/or functional impacts in human disease (23) and 128 ancestry informative markers (AIMs) (24) for population structure analysis. A customized 1152-plex chip was assembled using the Illumina GoldenGate platform. Genotyping was conducted using the Illumina Bead Station System in the Genomics Shared Resource at Roswell Park Comprehensive Cancer Center (Roswell Park). A total of 5% random duplicates and in-house trio samples were included in each run for quality control. The final analysis was performed on a total of 1045 SNPs in 2050 PCaP participants (993 AAs and 1057 EAs), after removing DNA samples (n=65) and SNPs (n=107) with call rate <95%. None of the SNPs included in the final analysis violated the Hardy-Weinberg equilibrium at $P < 0.05$. The 2050 DNA samples were: 1916 (93.5%) from blood, 102 (5%) from mouth wash, and 32 (1.5%) from immortalized lymphocytes derived from participants. No significant difference in distribution of DNA sources were found between AAs and EAs. Sensitivity analysis on participants with DNA samples from blood only (N=1916, 912 AAs and 1004 EAs) showed similar results, hence the results based on all 2050 DNA samples were presented.

Quantitative RT-PCR (qRT-PCR) analysis

Total RNA from 50 pairs of matched malignant and benign prostate tissues were requested from Roswell Park Pathology Network Shared Resource (PNSR) and subjected to qRT-PCR examination (25). The patients were self-reported non-Hispanic Whites (94%) primarily, 46% cases had primary Gleason grade 4, and 67% cases had tumor stage 3 and above. cDNA was generated using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA). Pre-made FAM-MGB real time PCR probes for 11 SLCO transporters and *GUS* as a housekeeping gene for reference were obtained from Thermo Fisher Scientific. Real time PCR reactions were set up using the Taqman Universal PCR Master Mix (Thermo Fisher Scientific) and run on an Applied Biosystems 7900HT Fast Real Time-PCR System (Foster City, CA).

In situ RNA hybridization

The RNAScope 2.5 HD Brown Assay kit and probes for human *SLCO2A1* and *SLCO5A1* were used, which is developed by Advanced Cell Diagnosis, Inc. (Newark, CA) by using specific probes to detect mRNA of genes of interest with high specificity. Images of stained sections were acquired using an Aperio ScanScope XT (Leica Biosystems, Buffalo Grove, IL), and processed using Aperio eSlide Manager (Leica Biosystems). *In situ* RNA hybridization was tested using a working tissue microarray (TMA) consisting of 10 PCa cases randomly selected by the PNSR with race information unavailable. Serial sections of Formalin-Fixed Paraffin-Embedded (FFPE)-procured PCa tissue specimen from two additional independent cases were requested from the PNSR to confirm *in situ* RNA hybridization results. Comparison of *in situ* expression by race was conducted using an immunohistochemistry (IHC) staining method as described in the next section.

IHC staining and quantification

A TMA set was constructed at PNSR using malignant and distant benign prostate tissue specimens from 92 AAs and 92 EAs. The TMA contained 3 cores of each type of tissue from each patient. Sections were requested for IHC staining for SLCO2A1 using a custom

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

antibody developed (0.0035 mg/mL) by Pacific Immunology (Ramona, CA), SLCO5A1 using antibody LS-C179257 (0.0017 mg/mL) from Lifespan Biosciences (Seattle, CA), and CD31 (an endothelial cell-specific marker) using antibody Dako M0823 (1:50) from Agilent (Santa Clara, CA). Relevant non-immune rabbit or mouse IgG were used as negative control. IHC staining was performed using a published method (25). Digital images of the stained sections were acquired using an Aperio ScanScope XT and captured using the Aperio Digital Image Analysis Software (Leica Biosystems Inc). Prostate epithelial cells in malignant and benign cores were circled manually under the supervision of a pathologist (Azabdaftari G.) and scored using algorithms optimized for SLCO2A1 and SLCO5A1 at PNSR.

Statistical analysis

Demographic and tumor characteristics were compared between AAs and EAs using Chi-squared tests for categorical variables and student *t*-tests for continuous variables if normally distributed, otherwise the Kruskal-Wallis tests were used. Genotype and allele frequency were compared between groups using Chi-squared tests and adjusted for multiple comparisons using Bonferroni correction. A total of 122 AIMs passed quality control and were analyzed using Structure v2.3.4 to ascertain genetic ancestry (26). A two-population model was assumed since there was a minimal Asian ancestry component found in the study population. Proportions of African and European ancestry were estimated for each PCaP participant and African ancestry proportion was included as a continuous covariate in statistical models.

For genetic analysis, primary outcomes were PCa aggressiveness (low/intermediate versus high), Gleason score (summary of primary and secondary Gleason grades, 8 versus < 8), primary Gleason grade (4 versus < 4), and clinical stage (T1/T2 versus T3/T4). Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) separately in AAs and EAs with adjustment of age at diagnosis (continuous), study site (NC or LA), first degree family history of PCa (yes or no), and African ancestry proportion (continuous). A genotypic (co-dominant) model was assumed, after which a dominant model was included with the consideration of small number of homozygotes for most of SNPs in the analysis. The common genotype in the EA group was used as the reference category for analyzing both AAs and EAs to facilitate comparisons between the groups. A log-additive genetic model was used to test genetic dose response by coding genotypes as 0, 1, 2 according to the number of variant alleles with P_trend presented. False discover rate (FDR) was applied for adjusting multiple comparisons and only SNPs with adjusted P values (P_adj) < 0.05 in either AAs or EAs were presented. Interaction between genotype and race was tested for significant SNPs in the models by including a relevant multiplicative term and P_interaction was generated using the Wald test of the product term for the differences in associations between AAs and EAs. The joint effects of significant SNPs were modeled using the number of risk alleles or genotypes as ordinal variables and were tested separately in AAs and EAs.

For qRT-PCR data, relative expression level of each SLCO transporter was presented as a ratio to the housekeeping gene of GUS as well as a percentage of the transporter relative to

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

the total expression of all SLCO transporters. The Wilcoxon signed-rank test was used for the comparisons between paired malignant and benign prostate tissues.

For IHC staining, H-scores were derived from the staining intensity (0, 1, 2, 3) multiplied by the percentage of positive cells for each intensity category. An average of H-scores was calculated from the three cores per patient for malignant tissue and for benign tissue, respectively. The Kruskal-Wallis test by rank was used to compare H-scores by cancer characteristics and between AAs and EAs. All analyses were conducted using the 64-bit build of R 3.6.2 and/or SAS 9.4 (Cary, NC).

Results

Characteristics of the study population of PCaP

Table 1 summarized the descriptive characteristics of the study population of PCaP by self-reported race information. Compared to EAs, AAs were diagnosed at younger ages (61.9 versus 64.2, $P < 0.001$) and had a higher percentage of cancer with aggressive phenotypes as defined by Gleason score 8, or PSA > 20 ng/mL, or Gleason score = 7 and clinical stage T3-T4 (21% versus 15%, $P < 0.001$). There were no differences in primary Gleason grade, Gleason score, clinical stage. AAs and EAs had similar rates of first-degree family history of PCa with the majority (approximately 75%) having no or unknown family history. The self-reported race status was consistent with the distribution of ancestry proportions determined by analysis of AIMs, showing predominant African or European ancestry. Similar results were obtained when association analysis was conducted using self-reported race status versus ancestry-based classification (e.g. 80% of African or European ancestry), indicating self-reported race status in PCaP could be a reasonable biological construct of race in the analysis of this population.

Association between genetic variants and PCa characteristics

Association analysis of the SNPs was performed separately in AAs and EAs with four cancer characteristics: PCa aggressiveness, primary Gleason grade, Gleason score and clinical stage (Supplementary Table S1 and S2). The results for primary Gleason grade were not included because of no significant SNPs in either AAs or EAs. Across the other three cancer characteristics, all significant SNPs belonged to two genes, *SLCO2A1* and *SLCO5A1* (Table 2). The SNP rs9917636, rs9874493, and rs3811662 in *SLCO2A1* were associated with reduced tumor aggressiveness, reduced Gleason score, or both, respectively; and all associations were observed only in AAs, of which associations of rs9917636 and rs3811662 differed significantly by race for tumor aggressiveness (P_interaction < 0.05). In contrast, 4 SNPs in *SLCO5A1* (rs16919172, rs4370538, rs4377973, rs10096246) were significantly associated with high clinical stage, but only in EAs. Of the four SNPs in *SLCO5A1*, the association between rs16919172 and clinical stage was significantly different between AAs and EAs (P_interaction < 0.05). The four SNPs in *SLCO5A1* (rs16919172, rs4370538, rs4377973, rs10096246) were in high LD in EAs but not AAs based on the 1000 Genomes Project (27), explaining the similar associations across the SNPs in EAs.

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Comparison of risk alleles/genotypes between AAs and EAs

Three significant SNPs in *SLCO2A1* in AAs had the common homozygote as the risk-genotypes: GG of rs3811662, AA of rs9874493, and AA of rs9917636; whereas, four significant SNPs in *SLCO5A1* in EAs had the minor allele as the risk-allele: G allele of rs10096246, rs16919172, rs4370538, and rs4377973. A summary of risk alleles or risk genotypes for identified SNPs and their frequencies in AAs and EAs was presented in Supplementary Table S3. The distributions of all SNPs except for rs9917636 in *SLCO2A1* were significantly different between AAs and EAs. The frequencies of risk-alleles/genotypes ranged from 0.23 to 0.72 (average 0.52) in AAs and was 0.06 in EAs. An overall higher frequency of risk-alleles/genotypes was observed in AAs.

Joint effect of risk alleles/genotypes on PCa characteristics

Three significant SNPs for *SLCO2A1* in AAs were modeled by combining the number of risk-genotypes (0-3) and using the group without any risk-genotype as the reference (Supplementary Table S4). A dose-dependent relationship with tumor aggressiveness was observed in AAs; the OR increased to 1.61 (95%CI, 0.90-2.89) with one, 1.96 (95%CI, 1.16-3.30) with two, and 3.49 (95%CI, 1.87-6.53) with three risk-genotypes in comparison to AAs without any risk-genotype. Although a similar trend was found for Gleason score and tumor stage, the number of events was too small to assess dose-dependent relationships. In EAs, no significant associations were observed for combined SNPs in *SLCO2A1*with any cancer characteristics, consistent with the results of single SNP analyses (Table 2).

The four significant SNPs for *SLCO5A1* in EAs had minor alleles as risk-alleles with frequencies about 0.06 and these risk-alleles were in high LD, so numbers were not sufficient to test for dose-dependent effects in EAs (Supplementary Table S4). Overall, EAs with at least one risk-allele had increased odds for worse cancer characteristics in comparison to EAs without a risk-allele in any of the four SNPs; however, only the association with tumor stage reached statistical significance (OR=6.59, 95%CI=2.51-17.28). None of these risk-alleles in *SLCO5A1* was associated individually with cancer characteristic outcomes in single SNP analyses for AAs (Table 2), but a significant association with tumor aggressiveness was appeared among AAs with the presence of 3 or more of the risk-alleles (OR=1.61, 95%CI=1.05-2.49) in comparison to AAs without any risk-alleles.

A dose-dependent relationship was found in AAs when risk alleles/genotypes in both *SLCO2A1* and *SLCO5A1* were combined for association analyses with PCa aggressiveness (Figure 1 and Supplementary Table S4). The odds for the aggressive phenotype of PCa was increased 14% per risk allele or genotype (OR=1.14, 95%CI=1.05-1.24). The association was observed in AAs only. For EAs, the significant associations were driven primarily by SNPs in *SLCO5A1*, no joint effect was observed between *SLCO2A1* and *SLCO5A1*.

Expression profile of SLCO transporters at the mRNA level in matched malignant and benign prostate tissues

Expression of all 11 SLCO transporters at the mRNA level was compared between the matched malignant and benign prostate tissue specimen from 50 patients (Table 3).

Author Manuscript

SLCO2A1 and *SLCO5A1* accounted for over 80% of all SLCO transporters expressed in prostate tissue regardless of malignant or benign status. Most other transporters were detected only with cycle threshold values between 35-40, and therefore were expressed at very low absolute levels. The overall expression of SLCO transporters at the mRNA level was lower in malignant than benign tissues (1.0 versus 1.6, $P < 0.001$). *SLCO2A1* and *SLCO5A1* followed the same pattern. However, when the percentages of SLCO2A1 and SLCO5A1 mRNA relative to total SLCO mRNA were compared between malignant and benign tissue, the percentage of SLCO5A1 mRNA was higher in malignant tissue (58.7%) than in benign tissue (50.4%); whereas, the percentage of SLCO2A1 mRNA was lower in malignant tissue (27.1%) than in benign tissue (37.6%). No significant differences were found at the mRNA level of all SLCO transporters by tumor stage or Gleason score. To note, the data were primarily pertinent to EAs as 47 out of 50 cases were self-reported non-Hispanic Whites (94%), although the data from the 3 AA cases showed similar patterns with the predominant expression of *SLCO2A1* and *SLCO5A1* in the prostate and no significant differences in the mRNA levels were observed between AAs and EAs.

In situ expression of SLCO2A1 and SLCO5A1 in PCa

In situ expression of SLCO2A1 and SLCO5A1 at the protein level was examined in serial sections of FFPE PCa tissue specimens using IHC (Figure 2A). SLCO5A1 was expressed predominantly in prostate epithelial cells and SLCO2A1 was expressed in both prostate epithelial and endothelial cells, but at a higher level in endothelial cells. Adjacent serial sections of FFPE PCa tissue specimens were used for *in situ* RNA hybridization for mRNA of SLCO2A1 (RNAScope) and IHC for the endothelial cell marker CD31, respectively, to confirm the expression of SLCO2A1 in endothelial cells (Figure 2B). Cells with more intensive RNAScope signals coincided with the CD31-positive cells, which indicated that SLCO2A1was expressed at higher levels in endothelial cells than in epithelial cells. Selective expression of SLCO5A1 in epithelial cells was also confirmed using RNAScope (Supplementary Figure S1). Overall, the expression localization pattern was similar between AAs and EAs, showing that SLCO2A1 was expressed predominantly in endothelial cells and at lower levels in epithelial cells, whereas, SLCO5A1 was expressed primarily in epithelial cells.

Expression of SLCO2A1 and SLCO5A1 at the protein level in PCa by race

Expression of SLCO2A1 and SLCO5A1 in malignant and benign prostate epithelial cells was compared between 92 AAs and 92 EAs (Figure 3). Each data point in the graph represents an average staining score from three cores per patient. Expression levels of SLCO5A1were significantly higher in EAs than AAs regardless of types of tissue, but no differences were found between benign and malignant cells for either AAs or EAs. which indicated that the difference in expression level between AAs and EAs might not be cancer specific. Higher expression of SLCO5A1 was found among EAs in patients with more aggressive phenotypes (Table 4) including primary Gleason grade (H-score 210 in 4 versus 182 in <4, P=0.037), Gleason score (216 in 8 versus 183 in <8, P=0.047), T stage (181 in T2, 199 in T3, 205 in T4, P=0.069), N stage (243 in N1 versus 193 in N0, P=0.017), in patients with failure after biochemical treatment (usually androgen deprivation therapy) (208 with failure versus 182 without failure, P=0.021), and in patients with radical prostatectomy

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

failure (203 with failure versus 182 without failure, *P*=0.03). In contrast, no significant findings for SLCO5A1 were observed in AAs. SLCO2A1 expression was similar between AA and EA, but slightly higher in benign than malignant tissue in AA (Figure 3). However, no significant differences were found across the panel of PCa characteristic phenotypes (Table 4). Endothelial cells were not sufficient to evaluate cell type-specific expression of SLCO2A1 due to the limited presence of endothelial cells in the TMA cores. Using Cox proportional hazards regression models for time to biochemical failure and time to radical prostatectomy failure with adjustment of age at surgery, tumor stage, summary Gleason score, pre-surgical PSA level, similar results were observed, showing that per standard deviation change in staining score of SLCO5A1 expression was associated with biochemical failure (HR 1.71, 95% CIs 1.10-2.67) and radical prostatectomy failure (HR 1.69, 95% CIs 1.10-2.61) in EAs, but not in AAs either with biochemical failure (HR 1.12, 95% CIs 0.77-1.64) or radical prostatectomy failure (HR 0.98, 95% CIs 0.70-1.39). No significant associations were found for SLCO2A1 in EAs or AAs. The results were aligned with the results of comparisons of SLCO2A1 and SLCO5A1 expression by tumor characteristics in AAs and EAs (Table 4). However, due to the small sample size (92 EAs and 92 AAs) and unavailable treatment data (radiation or chemotherapy), further validation is warranted.

Discussion

The study examined the relationships of the genotype and expression of SLCO transporters with phenotypes of PCa aggressiveness in AAs and EAs. At the genomic level, significant associations between SNPs and phenotypes of PCa aggressiveness were observed only for *SLCO2A1* and *SLCO5A1* out of all 11 SLCO transporters, and the associations significantly differed between AAs and EAs. SNPs in *SLCO2A1* were associated with reduced PCa aggressiveness and low Gleason score in AAs; whereas, SNPs in *SLCO5A1* were associated with advanced clinical stages in EAs. At the mRNA level, *SLCO2A1* and *SLCO5A1* were the predominantly expressed SLCO transporters in the prostate and the expression levels of the transporters differed significantly between the paired malignant and benign prostate tissues. At the tissue level, SLCO2A1 was expressed predominantly in endothelial cells, and at lower levels, in epithelial cells; whereas, SLCO5A1 was expressed primarily in epithelial cells. At the individual level, expression of SLCO5A1 was significantly higher in EAs than AAs in both malignant and benign prostate epithelial cells, and higher levels of expression were associated with more aggressive phenotypes of PCa only in EAs. Expression of SLCO2A1 was similar between EAs and AAs, and among the panel of tumor characteristics examined in the study. Since SLCO2A1 is expressed more preferentially in endothelial cells compared to epithelial cells, further investigation of the cell type-specific expression of SLCO2A1 in PCa could help explain the observed differential associations between SNPs in *SLCO2A1* and PCa aggressiveness in AAs and EAs.

SLCO2A1 and SLCO5A1 were among the least studied SLCO family members in PCa. Studies of SLCO transporters in PCa have been focused primarily on SLCO1B3 and SLCO2B1, and to a lesser extent on SLCO1A2, SLCO1B1, and SLCO4A1. These SLCO transporters have been reported as uptake transporters for androgens including testosterone (12,13) and dehydroepiandrosterone (28), and therapeutic drugs for treatment of PCa(14,29-37). SLCO transporters are known to have largely overlapping substrate profiles

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

(14,15), but the substrate specificity and the uptake efficiency for SLCO2A1 and SLCO5A1, particularly on androgen uptake, require further characterization. Interestingly, SNPs in *SLCO1B3* or *SLCO2B1* were reported to be associated with worse response to ADT (13,20,29) and shorter PCa-specific (17) and overall survival (12), but none of the SNPs in *SLCO1B3* or *SLCO1B1* was associated with cancer aggressiveness in either AAs or EAs in our study. A possible reason for association of genetic variations in *SLCO1B3* and *SLCO2B1* with PCa progression but not with cancer aggressiveness might be the very low expression of these transporters in the prostate, but their expressions increase as a result of PCa development, as shown in our data between matched benign to malignant tissue and shown in a study by Wright et al. between treatment-naïve and metastatic castration-resistant PCa (CRPC) tissue (17). Together, these findings suggest an important, but not yet defined, role of individual SLCO transporters in development and progression of PCa.

One of the intriguing findings of our study is that in comparison to AAs, EAs had significantly higher expressions of SLCO5A1 at the protein level in both malignant and benign prostate epithelial cells but had a lower percentage of more aggressive cancers. The hypothesized function of SLCO transporters is to regulate the availability of androgens to PCa cells, in that higher expression levels could result in more efficient uptake of androgens, and in turn lead to more aggressive PCa. This discrepancy might be explained partly by our observation of the cell type-specific expression of the two predominant SLCO transporters in PCa: SLCO2A1 in endothelial cells and SLCO5A1 in epithelial cells. The relative expression of the two transporters might coordinately determine the availability of androgens to PCa cells via regulation of the sequential transportation of androgen from the circulation to the prostate tissue microenvironment by the endothelial cell and from the tissue microenvironment to the cancer by the epithelial cell. Higher expression of SLCO5A1 in prostate epithelial cells in EAs may mitigate the reliance of SLCO2A1-mediated androgen transportation by endothelial cells from the circulation into the interstitial space, which explains the lack of association of genetic variations in *SLCO2A1* with PCa aggressiveness in EAs. In comparison, the lower expression of SLCO5A1 in epithelial cells of AAs may rely more on SLCO2A1in endothelial cells or the cooperation of SLCO2A1 and SLCO5A1 between endothelial and epithelial cells to obtain adequate tissue levels by elevated transport of androgen from the circulation. Indeed, a joint effect between risk alleles/genotypes in *SLCO2A1* and *SLCO5A1* was only observed in AAs, while for EAs, the significant associations were driven primarily by SNPs in *SLCO5A1*. Therefore, the race-specific associations of genetic variations in *SLCO2A1* and *SLCO5A1* are aligned with both transporters being the predominant SLCO transporters expressed in PCa tissue, and their cell type-specific expression in PCa endothelial cells and epithelial cells.

The cell type-specific expression of SLCO2A1 and SLCO5A1 in prostate tissue is supported by our recent report of RNA-Seq data generated from prostate epithelial cells and endothelial cells isolated from fresh clinical specimens of prostate tissue (38). However, knowledge on the biological functions and substrates of SLCO2A1 and SLCO5A1 in human prostate tissue is scant. SLCO2A1 was identified as a prostaglandin uptake transporter (39-41). Later identification of multiple SLCO2A1 inhibitors/blockers suggested the presence of other potential physiological substrates for SLCO2A1 in addition to prostaglandins (42-44). SLCO2A1 was reported to be expressed in endothelial cells (45) and

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

to be involved in tumor angiogenesis contributing to tumor growth in a mouse model of colorectal cancer (46). The observation in colorectal cancer is in line with our findings on a potential role for SLCO2A1 in endothelial cells in PCa aggressiveness. Physiologically relevant substrates for and function of SLCO5A1 are unclear. Some general SLCO substrates were tested and excluded as substrates for SLCO5A1 in SLCO5A1-overexressing *X. laevis* oocytes, including Prostaglandin E_2, estrone-3-sulfate, and dehydroepiandrosterone-3-sulfate (47). However, potential substrates for SLCO5A1 in PCa epithelial cells need to be evaluated *in situ*, since the expression of SLCO5A1 is cell-type specific and its substrate specificity might be a function dependent on the tissue microenvironment context.

Ideally, significant SNPs identified in genotype-phenotype association studies may point out directions for further functional characterization. However, all significant SNPs identified in the study in both *SLCO2A1* and *SLCO5A1* are located in introns, and none are in LD with potentially functional SNPs or coding SNPs based on the 1000 Genome Project and dbGap databases, nor in classical intron-exon juxtapositions that represent mRNA splice junctions. Further, these SNPs are unlikely to affect gene expression in that the risk-alleles/genotypes were present much more frequently in AAs (averagely 52%) than EAs (6%), while expression at the protein level was similar (SLCO2A1) or even lower (SLCO5A1) in AAs in comparison to EAs. In a sub-set of PCaP subjects (50 AAs and 58 EAs) that were genotyped for SLCO transporters and also had tumor tissues constructed in TMAs, IHC examination of SLCO2A1 and SLCO5A1 expression in the TMAs found that none of the significant SNPs was associated with gene expression. Therefore, the data further suggest that the identified SNPs may alter the transport function of SLCO2A1 and SLCO5A1 instead of affecting gene expression levels. Indeed, recent studies showed that a class of genetic variants termed “deep intronic variants”, does not exist in the classic splice junctions but nevertheless acts as regulatory sites to change the splicing phenotype (48-50). SNPs in other transporters, such as genes of SLCO1B3 and SLCO2B1, were found to alter the uptake rates of androgens and therapeutic agents (12,13), which supports a functional consequence of the SNPs identified in *SLCO2A1* and *SLCO5A1* in altering androgen uptake efficiency or substrate specificity. Since our study focused on common tag SNPs with MAF 0.05, the possibility of linkage with other unidentified rare genetic variants in these genes, in addition to the potential impact on splicing isoforms, cannot be excluded. Sequencing of the whole genes of *SLCO2A1* and *SLCO5A1* could help further delineate the signals and identify functional genetic variants.

In conclusion, we found that among all 11 SLCO family members, SLCO2A1 and SLCO5A1 may play important, but different, roles in PCa aggressiveness in AAs versus EAs. The finding calls for considerations of racial differences in biomarker studies of PCa and calls for further investigations on biological functions of SLCO2A1 and SLCO5A1 in the development and progression of PCa.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Acknowledgements

This research is supported by the Department of Defense Healthy disparity award (W81XWH-14-1-0453 to Y. Wu, and L. Tang), the National Cancer Institute (1R01CA193829 to G.J. Smith and Y. Wu), and Roswell Park Comprehensive Cancer Center Alliance Foundation (to L. Tang and Y. Wu). The research used data and samples from PCaP that is supported by the Department of Defense contract (DAMD 17-03-2-0052 to J. L. Mohler, J.T. Bensen, and E.T.H. Fontham). Additional resources were supported by Roswell Park Cancer Center Support Grant from the National Cancer Institute (P30CA016056).

The authors thank the staff, advisory committees and research participants in PCaP. The authors also thank the research staff in the Pathology Network Shared Resources and the Genomics Shared Resources at Roswell Park Comprehensive Cancer Center and in the Biospecimen Processing Facility at the University of North Carolina at Chapel Hill.

Financial support: PCaP is a collaborative study supported by the Department of Defense (DOD) contract DAMD 17-03-2-0052. The presented study is also supported by the DOD Healthy disparity award W81XWH-14-1-0453, 1R01CA193829-01A1 from the National Cancer Institute (NCI), and Roswell Park Comprehensive Cancer Center Alliance Foundation. The study used the Pathology Network Shared Resources and the Genomics Shared Resources supported by Roswell Park Cancer Center Support Grant from the NCI P30CA016056 and the University of North Carolina at Chapel Hill Biospecimen Processing Facility.

References

1. Howlader N, et al. SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.
2. Riviere P, et al. (2020) Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system. Cancer, 126, 1683–1690. [PubMed: 31984482]
3. Bhardwaj A, et al. (2017) Racial disparities in prostate cancer: a molecular perspective. Front Biosci (Landmark Ed), 22, 772–782. [PubMed: 27814645]
4. Heinlein CA, et al. (2004) Androgen receptor in prostate cancer. Endocr Rev, 25, 276–308. [PubMed: 15082523]
5. Mohler JL (2008) A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab, 22, 357–72. [PubMed: 18471792]
6. Mohler JL, et al. (2004) The androgen axis in recurrent prostate cancer. Clin Cancer Res, 10, 440–8. [PubMed: 14760063]
7. Kim HS, et al. (2011) Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. Prostate Cancer Prostatic Dis, 14, 262–5. [PubMed: 21519348]
8. Gaston KE, et al. (2003) Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol, 170, 990–3. [PubMed: 12913756]
9. Mohler JL, et al. (2004) Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol, 171, 2277–80. [PubMed: 15126802]
10. Parsons TK, et al. (2018) An active and selective molecular mechanism mediating the uptake of sex steroids by prostate cancer cells. Mol Cell Endocrinol.
11. Wu Y, et al. (2013) Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5alpha-reductase inhibitors. Prostate, 73, 1470–82. [PubMed: 23813697]
12. Hamada A, et al. (2008) Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res, 14, 3312–8. [PubMed: 18519758]
13. Yang M, et al. (2011) SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol, 29, 2565–73. [PubMed: 21606417]
14. Obaidat A, et al. (2012) The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol, 52, 135–51. [PubMed: 21854228]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

15. Roth M, et al. (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol, 165, 1260–87. [PubMed: 22013971]
16. Cho E, et al. (2014) Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression. Endocrinology, 155, 4124–32. [PubMed: 25147980]
17. Wright JL, et al. (2011) Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev, 20, 619–27. [PubMed: 21266523]
18. Pressler H, et al. (2011) Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One, 6, e20372. [PubMed: 21625523]
19. Fujimoto N, et al. (2013) Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation. Prostate Cancer Prostatic Dis, 16, 336–40. [PubMed: 23896625]
20. Sharifi N, et al. (2008) A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int, 102, 617–21. [PubMed: 18537956]
21. Schroeder JC, et al. (2006) The North Carolina-Louisiana Prostate Cancer Project (PCaP): methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes. Prostate, 66, 1162–76. [PubMed: 16676364]
22. D'Amico AV, et al. (1997) Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology, 49, 23–30. [PubMed: 9123732]
23. Yu W, et al. (2008) A navigator for human genome epidemiology. Nat Genet, 40, 124–5. [PubMed: 18227866]
24. Kosoy R, et al. (2009) Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat, 30, 69–78. [PubMed: 18683858]
25. Wu Y, et al. (2019) Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration. Mol Cell Endocrinol, 486, 79–88. [PubMed: 30807787]
26. Pritchard JK, et al. (2000) Inference of population structure using multilocus genotype data. Genetics, 155, 945–59. [PubMed: 10835412]
27. Genomes Project C, et al. (2015) A global reference for human genetic variation. Nature, 526, 68–74. [PubMed: 26432245]
28. Ugele B, et al. (2008) Functional differences in steroid sulfate uptake of organic anion transporter 4 (OAT4) and organic anion transporting polypeptide 2B1 (OATP2B1) in human placenta. J Steroid Biochem Mol Biol, 111, 1–6. [PubMed: 18501590]
29. Mostaghel EA, et al. (2017) Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clin Cancer Res, 23, 4592–4601. [PubMed: 28389510]
30. Khuri N, et al. (2017) Computational Discovery and Experimental Validation of Inhibitors of the Human Intestinal Transporter OATP2B1. J Chem Inf Model, 57, 1402–1413. [PubMed: 28562037]
31. Jabir RS, et al. (2012) Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics, 13, 1979–88. [PubMed: 23215890]
32. de Morree ES, et al. (2016) Loss of SLCO1B3 drives taxane resistance in prostate cancer. Br J Cancer, 115, 674–81. [PubMed: 27537383]
33. Lee HH, et al. (2015) Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance. Mol Cancer Ther, 14, 994–1003. [PubMed: 25695959]
34. Iusuf D, et al. (2015) Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel. Int J Cancer, 136, 225–33. [PubMed: 24825069]
35. de Graan AJ, et al. (2012) Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res, 18, 4433–40. [PubMed: 22711709]
36. Nieuweboer AJ, et al. (2014) Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res, 74, 3137–45. [PubMed: 24755470]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

37. van de Steeg E, et al. (2013) Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res, 19, 821–32. [PubMed: 23243220]
38. Gross NT, et al. (2020) Recapitulation of prostate tissue cell type-specific transcriptomes by an in vivo primary prostate tissue xenograft model. PLoS One, 15, e0233899. [PubMed: 32584883]
39. Nakanishi T, et al. (2017) Roles of Organic Anion Transporting Polypeptide 2A1 (OATP2A1/SLCO2A1) in Regulating the Pathophysiological Actions of Prostaglandins. AAPS J, 20, 13. [PubMed: 29204966]
40. Lu R, et al. (1996) Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest, 98, 1142–9. [PubMed: 8787677]
41. Kanai N, et al. (1995) Identification and characterization of a prostaglandin transporter. Science, 268, 866–9. [PubMed: 7754369]
42. Kamo S, et al. (2017) Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1/SLCO2A1. J Pharm Sci, 106, 2483–2490. [PubMed: 28479361]
43. Henry PJ, et al. (2005) Inhibitors of prostaglandin transport and metabolism augment protease-activated receptor-2-mediated increases in prostaglandin E2 levels and smooth muscle relaxation in mouse isolated trachea. J Pharmacol Exp Ther, 314, 995–1001. [PubMed: 15937152]
44. Chi Y, et al. (2006) Identification of a new class of prostaglandin transporter inhibitors and characterization of their biological effects on prostaglandin E2 transport. J Pharmacol Exp Ther, 316, 1346–50. [PubMed: 16269530]
45. Topper JN, et al. (1998) Human prostaglandin transporter gene (hPGT) is regulated by fluid mechanical stimuli in cultured endothelial cells and expressed in vascular endothelium in vivo. Circulation, 98, 2396–403. [PubMed: 9832484]
46. Nakanishi T, et al. (2017) A novel role for OATP2A1/SLCO2A1 in a murine model of colon cancer. Sci Rep, 7, 16567. [PubMed: 29185482]
47. Sebastian K, et al. (2013) Characterization of SLCO5A1/OATP5A1, a solute carrier transport protein with non-classical function. PLoS One, 8, e83257. [PubMed: 24376674]
48. Seo S, et al. (2013) Functional analysis of deep intronic SNP rs13438494 in intron 24 of PCLO gene. PLoS One, 8, e76960. [PubMed: 24167553]
49. Millar DS, et al. (2010) Characterisation of a functional intronic polymorphism in the human growth hormone (GH1) gene. Hum Genomics, 4, 289–301. [PubMed: 20650818]
50. Cooper DN (2010) Functional intronic polymorphisms: Buried treasure awaiting discovery within our genes. Hum Genomics, 4, 284–8. [PubMed: 20650817]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript



Figure 1.

Increase of Odds of aggressive phenotype of prostate cancer with the number of risk allele/ genotype in SLCO2A1 and SLCO5A1 in African Americans. Odds ratios were calculated using logistic regression with adjustment of age at diagnosis (continuous), study site (NC or LA), first degree family history of prostate cancer (Yes or no), and African ancestry proportion (continuous).

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript



Figure 2.
Differential expression of SLCO5A1 and SLCO2A1 in prostate endothelial cells and prostate epithelial cells. *In situ* expression of SLCO2A1 and SLCO5A1 was examined at the protein level using IHC (**2A**) and at the RNA level using RNAScope along with the endothelial cell marker CD31 using IHC (**2B**). Black and red arrows pointed to epithelial and endothelial cells, respectively.

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript



Figure 3.

Comparison of SLCO2A1 and SLCO5A1 expression in malignant and benign prostate tissues between African Americans and European Americans. Staining intensities, indicated by H-scores, were compared using the Kruskal-Wallis test by rank.

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Table 1.

Demographic and tumor characteristics of PCaP research participants by self-reported race

	African Americans (N=993)		European Americans (N=1057)		*P*_value[*]
	Mean	**SD**	**Mean**	**SD**	
Age at diagnosis, yrs	62	8	64	8	<0.001
European ancestry	0.098	0.160	0.975	0.086	<0.0001
African ancestry	0.902	0.160	0.025	0.086	<0.0001
	N	**%**	**N**	**%**	
Study site					0.416
North Carolina	436	43.9%	483	45.7%	
Louisiana	557	56.1%	574	54.3%	
Family history of PCa					0.299
No	656	66.0%	732	69.2%	
Yes	253	25.5%	246	23.3%	
Unknown	84	8.5%	79	7.5%	
Pre-treatment PSA level, ng/mL					<0.0001
<10	742	74.7%	890	84.2%	
10-20	140	14.1%	112	10.6%	
>20	111	11.2%	55	5.2%	
Primary Gleason grade					0.082
<4	770	80.0%	858	83.0%	
4	193	20.0%	176	17.0%	
Summary Gleason score					0.147
<8	861	86.9%	936	89.0%	
8	130	13.1%	116	11.0%	
Clinical stage					0.825
T1/T2	946	98.1%	1019	98.3%	
T3/T4	18	1.9%	18	1.7%	
PCa aggressiveness					0.0007
Low/intermediate	750	79.0%	872	84.9%	
High	199	21.0%	155	15.1%	

[*] Chi square tests were used for categorical variables, and student t-tests were used for continuous variables if normally distributed, otherwise Kolmogorov-Smirnov tests were used.

Table 2.

Differential associations of single-nucleotide polymorphisms in SLCO transporters with PCa characteristics between PCaP African Americans and European Americans

			European Americans				African Americans				
Gene	**SNP**	**Genotype**	**high vs low[e]**	**OR (95% CI)[a]**	***P*_trend[b]**	***P*_adj[c]**	**high vs low[e]**	**OR (95% CI)[a]**	***P*_trend[b]**	***P*_adj[c]**	***P*_interaction[d]**
Aggressiveness High vs. Low/Intermediate											
SLCO2A1	rs9917636	AA	33/231	1.00	0.896		62/150	1.00	**<0.001**	**0.03**	**0.004**
		AG	88/417	1.52 (0.98-2.36)			93/367	0.59 (0.41-0.86)			
		GG	34/222	1.04 (0.62-1.74)			44/233	0.45 (0.29-0.71)			
		AG/GG vs. AA	122/639	1.35 (0.89-2.05)			137/600	0.54 (0.38-0.77)			
SLCO2A1	rs3811662	GG	150/861	1.00	0.021		160/519	1.00	**0.001**	**0.039**	**0.004**
		GA	5/10	3.77 (1.22-11.64)			38/210	0.58 (0.39-0.86)			
		AA	0/0	N/A			1/20	0.16 (0.02-1.2)			
		GA/AA vs. GG	5/10	3.77 (1.22-11.64)			39/230	0.54 (0.37-0.8)			
Gleason score 8 vs. <8											
SLCO2A1	rs3811662	GG	114/922	1.00	0.574		108/603	1.00	**0.001**	**0.049**	0.218
		GA	2/13	1.55 (0.33-7.23)			22/235	0.52 (0.32-0.84)			
		AA	0/0	N/A			0/22	N/A			
		GA/AA vs. GG	2/13	1.55 (0.33-7.23)			22/257	0.47 (0.29-0.77)			
SLCO2A1	rs9874493	AA	84/671	1.00	0.967		94/518	1.00	**0.001**	**0.049**	0.352
		AG	30/243	1.04 (0.66-1.62)			36/294	0.66 (0.44-1)			
		GG	2/22	0.88 (0.2-3.85)			0/48	N/A			
		AG/GG vs. AA	32/265	1.02 (0.66-1.59)			36/342	0.56 (0.37-0.85)			
Stage 3/4 vs. 1/2											
SLCO5A1	rs16919172	AA	11/914	1.00	**<0.001**	**0.039**	15/729	1.00	0.604		**0.028**
		AG	7/101	6.24 (2.32-16.8)			3/199	0.78 (0.22-2.75)			
		GG	0/3	N/A			0/12	N/A			
		AG/GG vs. AA	7/104	5.98 (2.23-16.1)			3/211	0.74 (0.21-2.64)			
SLCO5A1	rs4370538	AA	10/901	1.00	**<0.001**	**0.035**	6/468	1.00	0.101		0.25
		AG	8/113	6.95 (2.64-18.3)			10/414	2.22 (0.77-6.36)			

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Gene	SNP	Genotype	European Americans				African Americans				
			high vs low[e]	OR (95% CI)[a]	*P*_trend[b]	*P*_adj[c]	high vs low[e]	OR (95% CI)[a]	*P*_trend[b]	*P*_adj[c]	*P*_interaction[d]
		GG	0/3	N/A			2/64	2.85 (0.54-14.9)			
		AG/GG vs. AA	8/116	6.67 (2.54-17.5)			12/478	2.31 (0.83-6.39)			
SLCO5A1	rs4377973	GG	11/908	1.00	**0.001**	**0.039**	6/447	1.00	0.331		0.383
		GC	7/108	5.93 (2.21-15.9)			11/422	2.28 (0.81-6.44)			
		CC	0/3	N/A			1/77	1.08 (0.13-9.32)			
		GC/CC vs. GG	7/111	5.68 (2.12-15.3)			12/499	2.09 (0.75-5.77)			
SLCO5A1	rs10096246	AA	11/911	1.00	**0.001**	**0.039**	10/572	1.00	0.526		0.078
		AG	7/105	6.04 (2.24-16.3)			7/336	1.29 (0.48-3.47)			
		GG	0/3	N/A			1/37	1.69 (0.20-14.0)			
		AG/GG vs. AA	7/108	5.79 (2.15-15.6)			8/373	1.33 (0.51-3.45)			

[a] ORs and 95% CIs were estimated from co-dominant and dominant models adjusting for age at diagnosis (continuous), state (NC or LA), 1st degree family history of PCa (yes/no), African ancestry proportion (continuous).

[b] *P*_trend was estimated for genetic dose response by coding genotypes as 0, 1, 2 according to the number of variant alleles.

[c] *P*_adj was generated from *P*-trend after correction for multiple comparisons by FDR. Only SNPs with *P*_adj less than 0.05 in either AAs or EAs were presented.

[d] *P*_interaction was calculated using Wald test of a multiplicative term for the differences in associations between AAs and EAs.

[e] high vs low indicated the number of events in each cancer characteristic group, e.g. number of cases with high aggressiveness versus number of cases with low/intermediate aggressiveness, number of cases with Gleason score 8 versus number of cases with Gleason score <8, and number of cases with stage 3/4 versus number of case with stage 1/2, respectively.

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3.

SLCO expression in 50 pairs of matched malignant and benign prostate tissues

	Malignant		Benign		
Gene	**Expression median (range)**	**Percentage (mean)**	**Expression median (range)**	**Percentage (mean)**	**P-value***
SLCO1A2	0.01 (0-0.5)	2.0	0.003 (0-0.1)	0.4	0.04
SLCO1B1	0 (0-0.02)	0.0	<0.001	0.0	0.16
SLCO1B3	0.004 (0-1.0)	1.8	0.001 (0-0.1)	0.3	0.001
SLCO1C1	<0.001	0.0	<0.001	0.0	0.07
SLCO2A1	**0.2 (0.02-5.3)**	**27.1**	**0.6 (0.04-6.6)**	**37.6**	**0.004**
SLCO2B1	0.004 (0-0.5)	1.9	0.004 (0-0.5)	1.5	0.33
SLCO3A1	0.03 (0-2.4)	5.0	0.08 (0-1.0)	5.9	0.003
SLCO4A1	0.01 (0-5.3)	3.1	0.03 (0-0.6)	3.5	0.003
SLCO4C1	0.002 (0-0.8)	0.4	0.002 (0-0.1)	0.4	0.13
SLCO5A1	**0.6 (0.1-7.6)**	**58.7**	**0.7 (0.04-6.7)**	**50.4**	**0.006**
SLCO6A1	<0.001	0.0	<0.001	0.0	0.79
Total	**1.0 (0.2-12.8)**		**1.6 (0.3-11.0)**		**<0.001**

*P values were calculated using Wilcoxon signed-rank test for paired samples.

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Table 4.

Expression of SLCO5A1 and SLCO2A1 in African Americans (AAs) and European Americans (EAs) with PCa

	SLCO5A1						SLCO2A1					
	AAs			EAs			AAs			EAs		
	N	H-Scores	P^	N	H-Scores	P^	N	H-Scores	P^	N	H-Scores	P^
Primary Gleason grade												
Low (<4)	71	116 (74-183)	0.748	69	182 (82-261)	**0.037**	69	145 (85-241)	0.248	67	171 (98-283)	0.648
High (>=4)	24	127 (85-192)		16	210 (119-268)		23	122 (96-226)		16	166 (104-240)	
Gleason score												
Low (<8)	82	116 (74-183)	0.439	78	183 (82-261)	**0.0466**	80	145 (85-241)	0.582	76	170 (98-283)	0.941
High (>=8)	13	124 (96-192)		7	216 (130-268)		12	131 (99-226)		7	169 (143-230)	
Pre-surgical PSA												
Low (< median)	47	115 (74-160)	0.374	41	182 (111-224)	0.1264	44	125 (85-241)	0.206	42	170 (102-247)	0.814
High (>= median)	47	118 (85-192)		45	189 (82-268)		47	148 (95-228)		42	171 (98-283)	
Age at operation *												
<50	16	118 (93-183)	0.486	4	172 (166-194)	0.123	15	134 (106-228)	0.617	4	160 (138-183)	0.349
50-59	47	115 (73-118)		41	176 (82-241)		46	138 (85-211)		41	169 (98-283)	
60-69	31	118 (85-183)		34	192 (111-261)		31	148 (99-241)		33	170 (104-251)	
>=70	1	135		7	210 (156-268)		0	N/A		7	186 (151-278)	
Pathological T stage												
T2	64	116 (74-183)	0.828	60	181 (82-254)	0.0678	62	148 (85-241)	0.276	59	171 (98-283)	0.495
T3	26	118 (85-192)		22	199 (118-268)		25	122 (99-207)		22	168 (110-251)	
T4	5	116 (87-183)		4	205 (157-222)		5	166 (95-185)		4	140 (119-197)	
Biochemical recurrence												
No	84	116 (74-192)	0.34	69	185 (82-268)	0.6733	83	133 (85-241)	0.259	68	170 (98-283)	0.596
Yes	9	124 (107-146)		16	184 (119-261)		7	155 (118-207)		16	166 (102-251)	
Biochemical failure												
No	63	116 (74-183)	0.418	57	182 (82-254)	**0.0212**	62	145 (85-241)	0.478	56	170 (98-283)	0.853
Yes	30	116 (87-192)		28	208 (118-268)		28	127 (95-207)		28	168 (102-251)	
Radical prostectomy failure												
No	56	116 (74-183)	0.543	55	182 (82-254)	**0.0303**	56	145 (85-241)	0.535	54	170 (98-283)	0.937

	SLCO5A1						SLCO2A1					
	AAs			EAs			AAs			EAs		
	N	**H-Scores**	**P^**	**N**	**H-Scores**	**P^**	**N**	**H-Scores**	**P^**	**N**	**H-Scores**	**P^**
Yes	37	116 (87-192)		30	203 (118-268)		34	131 (95-207)		30	168 (102-251)	

^ P values were calculated using Kruskal-Wallis tests by rank.

* Age at operation was significantly correlated with expression of SLCO5A1 (r=0.24) and 2A1 (r=0.26) in EAs but not AAs (r=0.03 and 0.04, respectively).

Author Manuscript Author Manuscript Author Manuscript Author Manuscript